一例成人患者因阿糖胞苷输注反应行脱敏治疗获得成功。
A successful desensitization in an adult patient with ARA-C infusion reaction.
机构信息
Division of Immunology and Allergic Diseases, Gulhane Training and Research Hospital, Ankara, Turkiye.
Division of Hematology, Gulhane Training and Research Hospital, Ankara, Turkiye.
出版信息
J Oncol Pharm Pract. 2024 Jun;30(4):780-782. doi: 10.1177/10781552241242691. Epub 2024 Mar 28.
INTRODUCTION
Cytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions.
CASE REPORT
47-year-old male patient with a diagnosis of B-cell Acute Lymphoblastic Leukaemia developed infusion reaction during ARA-C treatment.
MANAGEMENT & OUTCOME: There was no alternative treatment option for his existing malignant disease, we decided ARA-C desensitization.
DISCUSSION
We would like to describe a successful desensitization protocol in an adult patient who experienced a reaction during ARA-C infusion.
简介
阿糖胞苷（ARA-C）是一种抗代谢药物，尤其用于治疗血液系统恶性肿瘤。输注反应是治疗过程中可能发生的副作用之一。输注反应的临床特征类似于过敏反应。
病例报告
一位 47 岁男性患者，诊断为 B 细胞急性淋巴细胞白血病，在接受 ARA-C 治疗期间发生输注反应。
处理和结果
由于他患有恶性疾病，没有其他替代治疗方案，我们决定进行 ARA-C 脱敏治疗。
讨论
我们将描述一位成年患者在接受 ARA-C 输注时发生反应后的成功脱敏方案。
Zotero 插件